137 related articles for article (PubMed ID: 8514613)
1. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.
;
Jpn J Cancer Res; 1993 Apr; 84(4):455-61. PubMed ID: 8514613
[TBL] [Abstract][Full Text] [Related]
2. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
[TBL] [Abstract][Full Text] [Related]
3. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer.
Yamamoto H; Noguchi S; Miyauchi K; Inaji H; Imaoka S; Koyama H; Iwanaga T
Jpn J Cancer Res; 1991 Apr; 82(4):420-5. PubMed ID: 1828463
[TBL] [Abstract][Full Text] [Related]
4. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
5. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.
Rella C; Coviello M; Giotta F; Maiello E; Colavito P; Colangelo D; Quaranta M; Colucci G; Schittulli F
Breast Cancer Res Treat; 1996; 40(2):151-9. PubMed ID: 8879681
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer.
Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
Acta Oncol; 1993; 32(5):573-4. PubMed ID: 8217244
[No Abstract] [Full Text] [Related]
7. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
8. [Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers].
Ishizaki T; Itoh R; Yasuda J; Yamamoto T; Okada H
Gan To Kagaku Ryoho; 1992 Jun; 19(6):837-42. PubMed ID: 1534983
[TBL] [Abstract][Full Text] [Related]
9. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
[TBL] [Abstract][Full Text] [Related]
10. The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients.
Fukutomi T; Nanasawa T; Yamamoto H; Adachi I; Watanabe T
Jpn J Surg; 1990 Nov; 20(6):665-70. PubMed ID: 2150678
[TBL] [Abstract][Full Text] [Related]
11. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.
Tominaga T; Abe O; Ohshima A; Hayasaka H; Uchino J; Abe R; Enomoto K; Izuo M; Watanabe H; Takatani O
Eur J Cancer; 1994; 30A(7):959-64. PubMed ID: 7946592
[TBL] [Abstract][Full Text] [Related]
12. [Effects of combined hormone therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer].
Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
Gan To Kagaku Ryoho; 1993 May; 20(7):957-9. PubMed ID: 8489302
[No Abstract] [Full Text] [Related]
13. A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesteron acetate in advanced breast cancer.
Wils JA; Bron H; Van Lange L; Pannebakker M; Romme A; Scheerder H; Smeets JB; Beex LV
Cancer; 1985 Sep; 56(6):1325-31. PubMed ID: 3896455
[TBL] [Abstract][Full Text] [Related]
14. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
von Tempelhoff GF; Dietrich M; Hommel G; Heilmann L
J Clin Oncol; 1996 Sep; 14(9):2560-8. PubMed ID: 8823336
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
[TBL] [Abstract][Full Text] [Related]
17. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.
Falanga A; Toma S; Marchetti M; Palumbo R; Raffo P; Consonni R; Marziali S; Dastoli G; Barbui T
Am J Hematol; 2002 May; 70(1):9-15. PubMed ID: 11994976
[TBL] [Abstract][Full Text] [Related]
18. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
20. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
